WHO ICTRP trial
MInimal residual Disease Adapted Strategy / IFM 2020-02
CTIS2024-513889-19-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-513889-19-00 |
|---|---|
| Public title | MInimal residual Disease Adapted Strategy / IFM 2020-02 |
| Scientific title | MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM - MIDAS:IFM 2020-02 |
| Primary sponsor | Intergroupe Francophone Du Myelome |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No |
| Countries | Belgium;France |
| Conditions | Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104;Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15];Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: SARCLISA 20mg/mL concentrate for solution for infusion., Product Code:PRD8132765, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Isatuximab, Product Code:PRD10653408… |
| Registration date | Sep 19, 2024 |
| Target size | 791 |
| Secondary IDs | NCT04934475;2020-005216-21 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: